Related Experiment Video
Updated: Aug 18, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Diabetes in Canada: direct medical costs of major macrovascular complications
J A O'Brien1, I Caro, D Getsios
1Caro Research, 336 Baker Avenue, Concord, MA 01742, USA. jobrien@caroresearch.com
Insights
Managing major macrovascular complications in diabetic patients, such as acute myocardial infarction (AMI) and ischemic stroke, incurs significant direct medical costs in Canada. These costs highlight the economic burden of diabetes on the healthcare system.
Area of Science:
- Health Economics
- Cardiovascular Medicine
- Endocrinology
Background:
- Diabetes mellitus is a leading cause of macrovascular complications.
- These complications, including acute myocardial infarction (AMI) and ischemic stroke, impose substantial healthcare costs.
- Canadian-specific economic data for these complications are limited.
Purpose of the Study:
- To estimate the direct medical costs associated with managing major macrovascular complications in diabetic patients in Canada.
- To provide essential cost data for economic modeling and healthcare decision-making.
Main Methods:
- Cost estimation for AMI and ischemic stroke using unit costs and resource utilization data from Canadian sources.
- Inclusion of acute event costs (first year) and ongoing state costs.
- All costs reported in 1996 Canadian dollars.
Main Results:
- First-year management costs for AMI were approximately $15,125, with acute hospital care comprising about half.
- First-year management costs for ischemic stroke were approximately $31,076, with acute hospital care at 28% due to higher post-acute care needs.
- Annual state costs were $1,544 per patient for AMI and $8,141 per patient for stroke.
Conclusions:
- Macrovascular complications of diabetes represent a significant economic burden on Canada's healthcare system.
- Accurate, Canadian-specific cost data are crucial for evaluating new therapies and allocating healthcare resources effectively.
- This study provides key cost estimates to inform economic models for diabetes management in Canada.
Objectives:
To estimate direct medical costs of managing major macrovascular complications in diabetic patients.
Methods:
Costs were estimated for acute myocardial infarction (AMI) and ischemic stroke by applying unit costs to typical resource use profiles. Data were obtained from many Canadian sources, including the Ontario Case Cost Project, provincial physician and laboratory fee schedules, provincial formularies, government reports, and peer-reviewed literature. For each complication, the event costs per patient are those associated with resource use specific to the acute episode and any subsequent care occurring in the first year. State costs are the annual costs per patient of continued management. All costs are expressed in 1996 Canadian dollars.
Results:
Acute hospital care accounts for approximately half of the first year management costs ($15,125) of AMI. Given the greater need for postacute care, acute hospital care has less impact (28%) on event costs for stroke ($31,076). The state costs for AMI and stroke are $1544 and $8141 per patient, respectively.
Conclusions:
Macrovascular complications of diabetes potentially represent a substantial burden to Canada's health care system. As new therapies emerge that may reduce the incidence of some diabetic complications, decision makers will need information to make critical decisions regarding how to spend limited health care dollars. Published literature lacks Canadian-specific cost estimates that may be readily translated into patient-level cost inputs for an economic model. This paper provides two key pieces of the many needed to understand the scope of the economic burden of diabetes and its complications for Canada.
More Related Videos
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tg(fli:EGFP) Zebrafish Retinal Vasculature
Published on: December 26, 2017
04:36An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes: Symptoms, Diagnosis, and Complications
Type I Diabetes III: Clinical Manifestations
Complications of Diabetes Mellitus
Diabetic Retinopathy